- Premium Stock Alerts
- Posts
- Pre-Market Intel: Today’s Top Profit Opportunities!
Pre-Market Intel: Today’s Top Profit Opportunities!
Noor Saba
July 23, 2024
You are receiving this newsletter as a subscriber to Premium Stock Alerts
Hello Part-time Trader…👋
U.S. stock futures are mixed this Tuesday after the Magnificent 7's leading technology companies roared back to life at the start of the week.
In political news, markets are digesting the increasing likelihood of Kamala Harris becoming the Democrats' candidate to face Donald Trump in November's presidential election.
Today's a big earnings day, with automaker GM, beverage giant Coca-Cola, and GE Aerospace reporting before the bell, and EV titan Tesla along with Google parent Alphabet posting after the market close.
In stock-specific news, Tesla stock rises ahead of its second-quarter earnings, reports suggest Alphabet's talks to buy cybersecurity start-up Wiz have fallen apart, and UPS earnings miss estimates.
Happening Today
✓ 10:00 AM ET – Existing Home Sales (MoM) (Jun)
✓ 10:00 AM ET – Existing Home Sales (Jun)
✓ 01:00 PM ET – 2-Year Note Auction
✓ 04:30 PM ET – API Weekly Crude Oil Stock
One everyday trader just developed a new way to use AI to take advantage of a powerful market anomaly that has been quietly studied by Harvard, Duke University, the SEC, and even the Federal Reserve. See how he was able to beat the stock market by 17x, right from his home in a small town.
See the remarkable discovery.
Sponsored
PREMARKET SNAPSHOT📈
Market futures are slightly up, with the S&P 500, Dow, and NASDAQ all showing modest gains.
S&P500$5616.00 ⬆️ 0.09% | Dow$40730.00 ⬆️ 0.09% | NASDAQ$20001.00 ⬆️ 0.01% |
SECTOR SNAPSHOT✨
The market rebounded strongly with broad-based gains. Information Technology led the charge with impressive performance, followed by significant increases in Industrials and Communication Services. Consumer Discretionary and Financials also posted solid gains. Health Care and Real Estate contributed to the positive momentum, reflecting overall market optimism. Despite minor declines in Energy and Consumer Staples, the day was marked by a strong upward trend across most sectors.
NAME | PRICE | %CHANGE |
|---|---|---|
Consumer Discretionary | 1,525.50 | +0.87% 🟢 |
Consumer Staples | 836.12 | -0.04% 🔴 |
Energy | 701.44 | -0.72% 🔴 |
Financials | 717.25 | +0.64% 🟢 |
Health Care | 1,732.57 | +0.57% 🟢 |
Industrials | 1,067.90 | +1.07% 🟢 |
Materials | 569.67 | +0.34% 🟢 |
Real Estate | 256.68 | +0.98% 🟢 |
Information Technology | 4,382.84 | +1.96% 🟢 |
Communication Services | 305.51 | +1.20% 🟢 |
Utilities | 359.34 | +0.87% 🟢 |
This tiny AI company is quietly trading at a market cap under $70M but this analyst says it's worth at least $244M! Considering that the CEO sold his last company to Microsoft, mega growth potential doesn't seem too far off. Now is the time to get the ticker before it's too late.
Find more information HERE.
Sponsored
PreMarket Unusual Volume Stocks
📈 Warrantee Inc ADR (WRNT): Warrantee Inc ADR saw an extraordinary surge in trading activity with a volume of 23,191,644, far surpassing its average volume of 123,250. This massive uptick in interest resulted in a significant 172.47% price change, reflecting heightened market interest.
📈 Nature's Miracle Holding Inc (NMHI): Nature's Miracle Holding Inc experienced a substantial rise in volume, trading 10,283,676 shares compared to its average of 81,940. This dramatic increase in trading volume resulted in a 92.03% price change, indicating strong investor activity.
📈 Brera Holdings PLC (BREA): Brera Holdings PLC saw its trading volume surge to 1,806,720, significantly higher than its average of 27,530. Despite the increased trading activity, the stock experienced a -21.96% price change.
📈 Gamer Pakistan Inc (GPAK): Gamer Pakistan Inc's volume spiked to 9,247,481, a substantial increase from its average of 213,990. The stock's 191.87% price change highlights the impact of the increased trading activity.
📈 Volato Group Inc (SOAR): Volato Group Inc saw its volume rise to 10,114,362, far exceeding its average of 452,580. The stock's 75.85% price change reflects the surge in trading volume.
Hundreds of new traders have adopted this unique new way to trade Tesla shares. In 2024 it's shown opportunities to collect substantial gains in as little as 6 days. The next trade is scheduled for this Thursday.
Click here for details
Sponsored
Premarket Picks
Nature's Miracle Holding Inc. (NMHI) saw its stock soar by approximately 111.91% in pre-market trading, reaching over $0.73 per share after filing an S-1/A form with the SEC.
Frequency Electronics, Inc. (FEIM) experienced a pre-market jump of nearly 36.63%, rising to $13.80 per share after announcing its fourth quarter and full fiscal year 2024 financial results.
Mammoth Energy Services, Inc. (TUSK) enjoyed a pre-market increase of about 36.29%, with its stock price climbing above $4.77 after its subsidiary, Cobra Acquisitions LLC, settled all issues with the Puerto Rico Electric Power Authority and the Financial Oversight and Management Board for Puerto Rico.
Spotify Technology S.A. (SPOT) saw its stock skyrocket by 13.05% in pre-market trading, reaching $334.00 per share after releasing its financial results for the second quarter of 2024.
Below is a list of other hot stocks in pre-market today:
Pre Market Gainers | Pre Market Change | Pre Market Volume |
|---|---|---|
NMHI | +127.00% | 8.04M |
SOAR | +79.89% | 6.98M |
LIFW | +4.07% | 4.72M |
HOVR | +7.99% | 976.13K |
CEI | +3.22% | 163.32K |
JAGX | +6.56% | 146.65K |
GM | +4.32% | 113.12K |
SMR | +4.07% | 112.73K |
SYTA | +5.05% | 92.87K |
FEIM | +31.88% | 74.43K |
5% plus yields might seem like an easy way to boost investment income, but they can be traps. This report highlights 20 stocks paying unsustainably high dividends, with payouts exceeding 100% of their earnings, indicating these yields likely won't last.
Get Your Copy of "20 High-Yield Dividend Stocks that Could Ruin Your Retirement" Here.
Sponsored
Important FDA
Recently Announced
In a win for Phathom Pharmaceuticals (PHAT), their VOQUEZNA tablets received FDA approval on July 18th, 2024. This green light allows VOQUEZNA to be used for treating non-erosive GERD-related heartburn in adults.
Arcutis Biotherapeutics (ARQT) secured FDA approval for their Roflumilast Cream 0.15% on July 9th, 2024. This topical cream provides a fresh treatment avenue for managing mild to moderate atopic dermatitis in both adults and children as young as six. This approval broadens the treatment options available for this chronic skin condition.
On June 28th, 2024, Rocket Pharmaceuticals (RCKT) faced a hurdle when the FDA issued a Complete Response Letter (CRL) for their drug KRESLADI (RP-L201). This drug was being evaluated for treating Leukocyte Adhesion Deficiency-I, a rare genetic disorder. The CRL signifies that the FDA requires further information or adjustments before approving the treatment.
Positive news came for AbbVie (ABBV) on June 26th, 2024, as the FDA approved an expanded use for their drug Epcoritamab-bysp. This approval allows the drug to be used for adult patients with relapsed or refractory follicular lymphoma (FL) who have undergone at least two prior lines of systemic therapy. This offers new hope for patients who have exhausted other treatment options.
Some of the greatest opportunities can be found in undervalued stocks.
Often, a stock will become undervalued because of negative events, like the pandemic. Perhaps the company missed earnings, became overlooked, or was hit with downgrades. Or, maybe the stock fell along with its competition.
Here are five of the most exciting, cheap stocks you may want to take a look at today.
Download Free Report
Sponsored
Upcoming Announcements
A major event for AstraZeneca (AZN.L, AZN) is coming up on July 25th, 2024. The FDA panel will be reviewing IMFINZI, a drug being evaluated for use in combination with chemotherapy as a neoadjuvant treatment, as well as monotherapy post-surgery, for adult patients with resectable non-small cell lung cancer. The panel's decision could significantly impact treatment approaches for this type of cancer.
scPharmaceuticals Inc. (SCPH) awaits a crucial FDA decision in August 2024. The decision concerns the expansion of FUROSCIX's use to encompass patients with New York Heart Association Class IV heart failure. This expansion has the potential to significantly increase treatment options for this severe heart failure stage.
Zevra Therapeutics, Inc. (ZVRA) anticipates an FDA panel review on August 2nd, 2024, for their drug Arimoclomol. This drug is being studied as a treatment for Niemann-Pick disease type C, a rare and progressive genetic disorder. The outcome of this review will be critical for patients and families battling this condition.
Adaptimmune Therapeutics plc (ADAP) is set for an FDA decision on August 4th, 2024, regarding Afami-cel. This drug is being evaluated for use in treating advanced synovial sarcoma. The decision will determine if Afami-cel can be approved as a new treatment option for this aggressive form of cancer.
Happy investing,
Maeve Grace
Editor In Chief
Premium Trade Alerts
Important: This newsletter does not provide investment advice. The stocks mentioned should not be taken as recommendations. Your investments are solely your decisions.
Disclosure: I hold no positions in any companies mentioned, either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.
Reply